You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back


Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients). [1]


  1. Fendrix Summary of Product Characteristics. Available from: Last accessed - January 2017

Fendrix is a registered trademark of the GlaxoSmithKline group of companies